Cytokine-induced Killer T Cells Enhance the Cytotoxicity Against Carboplatin-resistant Ovarian Cancer Cells

• Published in: Anticancer research Vol. 40; no. 7; pp. 3865 - 3872
• Main Authors: PAN, YUEH, CHIU, YA-HSU, CHIU, SHAO-CHIH, CHO, DER-YANG, LEE, LIANG-MING, WEN, YU-CHING, WHANG-PENG, JACQUELINE, HSIAO, CHI-HAO, SHIH, PING-HSIAO
• Format: Journal Article
• Language: English
• Published: Athens International Institute of Anticancer Research 01.07.2020
• Subjects: Cancer; Cancer therapies; Carboplatin; Cell therapy; Chemotherapy; Cytokines; Cytotoxicity; Flow cytometry; Interferon; Interleukin 2; Leukocytes (mononuclear); Lymphocytes; Lymphocytes T; Ovarian cancer; Peripheral blood mononuclear cells; Toxicity; γ-Interferon
• ISSN: 0250-7005; 1791-7530
• DOI: 10.21873/anticanres.14376

Background/Aim: Ovarian cancer (OC) is typically diagnosed at an advanced stage with limitations for cure. Cytokine-induced killer (CIK) T cell therapy exerts significant cytotoxic effects against cancer cells and reduces the adverse effects of chemotherapy. Herein, we performed a flow cytometry-based method to evaluate the cytotoxicity of peripheral blood mononuclear cells-derived CIK cells against OC cells. Materials and Methods: The CIK cells were induced and expanded using an interferon-γ/IL-2-based xeno-free medium system. The cytotoxicity of CIK cells or carboplatin against OC cells was examined. Results: The CIK cells showed an NK-like phenotypic characteristic and dose-dependently increased cytotoxicity against OC cells. We found that the number of advanced OC cells, which were more resistant to carboplatin, was dramatically decreased by an additional one-shot CIK treatment. Conclusion: CIK cells have a potent cytotoxic ability that would be explored as an alternative strategy for cancer treatment in the near future.